Drug Profile
Octreotide - QLT USA
Alternative Names: Atrigel-Octreotide; Octreotide depot - QLT USALatest Information Update: 02 Oct 2021
Price :
$50
*
At a glance
- Originator QLT USA
- Class Antidiarrhoeals; Antineoplastics; Antisecretories; Cyclic peptides; Eye disorder therapies; Indoles; Somatostatins
- Mechanism of Action Growth hormone-releasing hormone inhibitors; Somatostatin receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acromegaly; Malignant carcinoid syndrome
Most Recent Events
- 18 Aug 2006 Phase-I clinical trials in Acromegaly in Russia (Intralesional)
- 22 May 2006 QLT has delayed initiation of a phase IIa study of octreotide in patients with acromegaly
- 22 Nov 2004 Atrix Laboratories has been acquired by QLT